首页> 美国卫生研究院文献>BMC Molecular Biology >Alternative splicing of the neurofibromatosis type 1 pre-mRNA is regulated by the muscleblind-like proteins and the CUG-BP and ELAV-like factors
【2h】

Alternative splicing of the neurofibromatosis type 1 pre-mRNA is regulated by the muscleblind-like proteins and the CUG-BP and ELAV-like factors

机译:1型神经纤维瘤病前mRNA的选择性剪接受肌肉盲样蛋白以及CUG-BP和ELAV样因子的调控

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundAlternative splicing is often subjected to complex regulatory control that involves many protein factors and cis-acting RNA sequence elements. One major challenge is to identify all of the protein players and define how they control alternative expression of a particular exon in a combinatorial manner. The Muscleblind-like (MBNL) and CUG-BP and ELAV-Like family (CELF) proteins are splicing regulatory proteins, which function as antagonists in the regulation of several alternative exons. Currently only a limited number of common targets of MBNL and CELF are known that are antagonistically regulated by these two groups of proteins.
机译:背景技术选择性剪接通常受到复杂的调控控制,涉及许多蛋白质因子和顺式作用RNA序列元件。一个主要的挑战是识别所有蛋白质参与者,并定义它们如何以组合方式控制特定外显子的替代表达。 Muscleblind-like(MBNL)和CUG-BP和ELAV-Like家族(CELF)蛋白是剪接调节蛋白,其在几种其他外显子的调节中起拮抗剂的作用。目前,只有有限数量的MBNL和CELF共同靶标被这两组蛋白质拮抗调节。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号